Who is sponsoring NCT05662943?

NCT05662943 is sponsored by Kim's Eye Hospital.

What drugs are being tested in NCT05662943?

Interventions in NCT05662943: Intravitreal aflibercept injection.

What condition does NCT05662943 study?

NCT05662943 studies Polypoidal Choroidal Vasculopathy, Choroidal Neovascularization, Age-Related Macular Degeneration.

Is NCT05662943 still recruiting?

NCT05662943 is currently completed. Last updated 14 December 2023.

Last reviewed 2023-12-14 · How we verify

NCT05662943

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Completed Last updated 14 December 2023

What this trial tests

trial testing Intravitreal aflibercept injection in Polypoidal Choroidal Vasculopathy in 135 participants. Completed in 30 November 2023.

Timeline

5 December 2022

Primary endpoint
31 May 2023

30 November 2023

Quick facts

Lead sponsor	Kim's Eye Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	135
Start date	5 December 2022
Primary completion	31 May 2023
Estimated completion	30 November 2023
Sites	1 location across South Korea

Drugs / interventions tested

Intravitreal aflibercept injection — full drug profile →

Conditions studied

Polypoidal Choroidal Vasculopathy — all drugs for Polypoidal Choroidal Vasculopathy →
Choroidal Neovascularization — all drugs for Choroidal Neovascularization →
Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →

Sponsor

Kim's Eye Hospital

Who can join

50 and older, any sex, with Polypoidal Choroidal Vasculopathy or Choroidal Neovascularization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration.
Lee JH, Kim JH. · · 2024 · cited 3× · PMID 38489060 · DOI 10.1089/jop.2023.0124

Verify or expand the search:

Other trials of Intravitreal aflibercept injection

Trials testing the same drug.

NCT04580147 — Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair · Phase 2 · unknown
NCT03405376 — Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion · Phase 4 · unknown

Other Kim's Eye Hospital trials

Trials by the same sponsor.

NCT07187804 — Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization · Phase 4 · not yet recruiting
NCT06683950 — Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment · Phase 4 · recruiting
NCT05662410 — Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy · Phase 4 · completed
NCT04655482 — Treat-and-extend Using Aflibercept for Type 3 Neovascularization · Phase 4 · unknown
NCT04836143 — Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05662943 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kim's Eye Hospital
Last refreshed: 14 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05662943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing